Evidence map›Paper›PMID 26424170›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.

Costel Chirila, Qingyao Zheng, Eric Davenport, Dagmar Kaschinski, Egon Pfarr, Thomas Hach, Roberto Palencia

Open access · hybridFull text readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 4 countries.

Costel ChirilaRTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA. cchirila@rti.org.
Qingyao ZhengRTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA.
Eric DavenportRTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA.
Dagmar KaschinskiBoehringer Ingelheim GmbH, Binger Str. 173, 55216, Ingelheim am Rhein, Germany.
Egon PfarrBoehringer Ingelheim Pharma GmbH & Co. KG, Binger Str. 173, 55216, Ingelheim am Rhein, Germany.
Thomas HachBoehringer Ingelheim Pharma GmbH & Co. KG, Binger Str. 173, 55216, Ingelheim am Rhein, Germany.
Roberto PalenciaBoehringer Ingelheim GmbH, Binger Str. 173, 55216, Ingelheim am Rhein, Germany.
Boehringer Ingelheim (Germany) · DERTI Health Solutions · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis exploratory analysis assessed and compared patients' treatment satisfaction with empagliflozin plus metformin versus glimepiride plus metformin, using data obtained from the Diabetes Treatment Satisfaction Questionnaire, status version (DTSQs) collected in a randomized, double-blind, double-dummy clinical trial.

methodsObserved values for DTSQs scale score and each of its eight items were summarized by visit and treatment arm. Changes from baseline in these scores were analyzed using linear mixed models for repeated measures.

resultsThe baseline scale score and item scores were comparable between empagliflozin plus metformin (n = 765) and glimepiride plus metformin (n = 780). Compared with baseline, patients reported significant treatment satisfaction increases and significant decreases in perceived hyperglycemia with both treatments at all visits. Also, compared with baseline, a significant increase in perceived frequency of hypoglycemia was observed in the glimepiride treatment group at all visits. No statistically significant treatment difference was observed in DTSQs scale score and its items at week 104. The difference between the treatment groups was significant and in favor of empagliflozin from week 28 onward for perceived frequency of hyperglycemia (P ≤ 0.006) and perceived frequency of hypoglycemia (P ≤ 0.011).

conclusionsDespite positive trends in favor of empagliflozin, there was no significant difference in DTSQs scale score between empagliflozin and glimepiride at 104 weeks. However, when compared with glimepiride, empagliflozin demonstrated significantly lower perceived frequency of hyperglycemia and hypoglycemia at all visits from week 28 onward. This finding is consistent with the clinical results reported for the EMPA-REG H2H-SU trial.

Indexed as

Personal SatisfactionAdultBenzhydryl CompoundsClinical ProtocolsDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleGlucosidesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsMaleMetforminBenzhydryl CompoundsempagliflozinglimepirideGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsMetforminSulfonylurea CompoundsDiabetes Treatment Satisfaction QuestionnaireEmpagliflozinGlimepirideType 2 diabetes mellitus

Identifiers

PMID26424170
PMCPMC4840220
OpenAlexW1831536039

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.